Brief: Ascentage Pharma Group International Says CDE Of NMPA Approved Clinical Study Of Class 1 Novel MDM2-P53 Inhibitor APG-115
02/12/2020 01:04
Dec 2 (Reuters) - Ascentage Pharma Group International
6855.HK :
* CENTER FOR DRUG EVALUATION OF NMPA APPROVED CLINICAL STUDY
OF
CLASS 1 NOVEL MDM2-P53 INHIBITOR APG-115
Source text for Eikon: ID:nHKS2mcvRK
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up